基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗

智通财经03-25

智通财经APP讯，基石药业-B(02616)发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会(ESMO)指南的【I, A】级推荐。此次，舒格利单抗被纳入《早期及局部晚期非小细胞肺癌动态临床指南》(Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline)，用于III期非小细胞肺癌(NSCLC)患者在同步...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622292100?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-25 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622292100","market":"us","top_or_hot":-1,"title":"基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗","media":"智通财经","content":"<div>\n<p>智通财经APP讯，基石药业-B(02616)发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会(ESMO)指南的【I, A】级推荐。此次，舒格利单抗被纳入《早期及局部晚期非小细胞肺癌动态临床指南》(Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline)，用于III期非小细胞肺癌(NSCLC)患者在同步...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418760.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n基石药业-B(02616)：舒格利单抗再获ESMO指南【I， A】推荐 ——用于III期非小细胞肺癌巩固治疗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-25 17:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1418760.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，基石药业-B(02616)发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会(ESMO)指南的【I, A】级推荐。此次，舒格利单抗被纳入《早期及局部晚期非小细胞肺癌动态临床指南》(Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline)，用于III期非小细胞肺癌(NSCLC)患者在同步...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1418760.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1418760.html","article_id":"2622292100","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622292100","pubTimestamp":1774430400,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，基石药业-B 发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会指南的级推荐。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK4134":"信息科技咨询与其它服务","02616":"基石药业-B","III":"信息服务"},"translate_title":"CStone Pharmaceuticals-B (02616): Sugaglimab is recommended again by ESMO guidelines [I, A] for consolidation treatment of stage III non-small cell lung cancer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"02616":1.5},"content_text":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心商业化产品舒格利单抗获得欧洲肿瘤内科学会(ESMO)指南的【I, A】级推荐。此次，舒格利单抗被纳入《早期及局部晚期非小细胞肺癌动态临床指南》(Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline)，用于III期非小细胞肺癌(NSCLC)患者在同步或序贯放化疗后的巩固治疗。该推荐将显著助力舒格利单抗在欧盟及其他市场的准入进程，惠及更广泛的患者群体,，从而为其全球商业化拓展提供坚实支援。2025年2月，舒格利单抗联合化疗已获得ESMO《非驱动基因阳性转移性非小细胞肺癌动态临床指南》的【I, A】推荐，用于鳞状及非鳞状IV期非小细胞肺癌双适应症的一线治疗。至此，舒格利单抗在欧盟及英国获批的两项肺癌适应症均已被纳入ESMO指南，充分体现了其临床价值。根据最新版ESMO指南明确推荐：EGFR野生型、无ALK或ROS1基因突变的III期NSCLC患者，若在接受同步或序贯放化疗后未出现疾病进展，可采用舒格利单抗进行巩固治疗，治疗持续时间最长不超过24个月。该推荐适用于肿瘤细胞(TC)PD-L1表达水准≥1% 的患者【ESMO-临床获益量表(MCBS)v2.0评分：3分;已获欧洲药品管理局(EMA)批准】，证据等级为【I, A】。指南中的治疗推荐是基于关键性III期临床试验GEMSTONE-301的研究结果，该研究证实，舒格利单抗用于III期NSCLC巩固治疗，能够为患者带来具有统计学意义的无进展生存期(PFS)改善和具有临床意义的总生存期(OS)延长。截至目前，舒格利单抗已在欧洲、中东及非洲、拉丁美洲达成四项商业化合作，商业化网路已拓展至全球六十余个国家和地区，其市场准入申请也已在十余个国家获批或进入审评阶段，海外商业化布局正在稳步、高效推进中。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622292100","isCrawlerRequest":true}